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Summary 
Increasing access to online sources and social net-
works are changing the environment of rare diseases 
research. Patient- and parent-networks use these new 
resources not only to access health information but 
also to initiate and conduct research. Using current ex-
amples of patient or parent-led research (PLR) beyond 
clinical research, we summarize and discuss potential 
benefits and pitfalls of PLR.  
Epileptologie 2015; 32: 177 – 182
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La révolution prometteur du “participant-led 
research” sur les maladies neurologiques rares; 
Avantages et les pièges potentiels
Accroître l’accès aux sources en ligne et les réseaux 
sociaux sont en train de changer l’environnement de la 
recherche sur les maladies rares. Réseaux de parents et 
patients utilisent ces nouvelles ressources non seule-
ment d’accéder aux informations de santé, mais aussi 
d’initier et de mener des recherches. En utilisant des 
exemples actuels de recherché conduit pare les pa-
tients ou parents (participant/parent-led research, PLR) 
au-delà de la recherche clinique, nous résumons et dis-
cutons des avantages et les pièges de PLR. 
Mots clés : Participant-led research, éthique de la recher-
che, financement par la collectivité, citoyen scientifique, 
autorité parentale, intérêt supérieure de l’enfant
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The Promising Revolution of Participant-Led Research in Rare Neurological Diseases; 
Potential Benefits and Pitfalls 
Die vielversprechende Revolution von “Partici-
pant-Led Research” in seltenen neurologischen 
Erkrankungen: Mögliche Chancen und Probleme. 
Der deutlich erleichterte Zugang zu Informationen 
via Internet und Netzwerke verändert das Umfeld für 
Forschung zu seltenen Krankheiten. Patienten- und El-
terngruppen verwenden die neuen Möglichkeiten nicht 
nur als Tor zu gesundheitsrelevantem Wissen, sondern 
auch um Forschungsprojekte zu fördern, zu planen und 
durchzuführen. Mit Hilfe aktueller Beispiele von Patien-
ten- und Eltern-geführter Forschung beleuchten und 
diskutieren wir die daraus entstehenden Chancen und 
Probleme.   
Schlüsselwörter: Participant-led research, Forschungse-
thik, crowd funding, citizen science, im besten Interesse 
des Kindes, Elternautonomie
“[The health care service] of the future will be one of pa-
tient power, patients engaged and taking control over 
their own health and healthcare.” 
Gordon Brown, Former U.K. Prime Minister (cited from 
Swan 2008)
Introduction 
Epilepsy and epilepsy syndromes belong to the 
most common neurological disorders. The underlying 
cause, however, remains obscure for a large portion 
of patients [1]. The focus on functional and molecular 
mechanisms in etiologic research shares a common 
denominator with other rare diseases [2]. While each 
rare disease is rare, taken together they are common. 
Estimations range between 27 to 36 million people 
affected in the EU by a spectrum of 5000 to 8000 dis-
tinct rare diseases [3]. These patients are particularly 
exposed to the global crisis in drug development with 
exponentially rising costs after the discovery and de-
velopment of new pharmaceutical drugs has plateaued 
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(so-called “low hanging fruit” principle). In response to 
this development, treatment and research centres for 
rare diseases are being established [4].
However, despite great efforts in forming networks 
of specialized centres, and despite tremendous general 
advances in biomedicine, rare diseases and rare neu-
rological disorders in particular remain an area where 
therapeutic  progress has been slow. There is still a 
great need for basic and translational research in rare 
diseases. Currently there are six stakeholders, which 
propose, enforce and initiate research projects on rare 
disease: The research institution (1), advocacy groups 
(2), patients and their families (3), health care profes-
sionals (4), funding bodies (5) and the state (6). In re-
cent years legislative incentives in both USA and the Eu-
ropean Union have stimulated research initiatives and 
the formation of networks, including projects particu-
larly focusing on rare neurologic diseases (e.g. http://
www.eurordis.org/content/european-network-rare-
paediatric-neurological-diseases-neuroped or http://
www.epilepsy.com/ren). However, more consorted ef-
forts are still needed. Our article focuses on the new 
movement of systematic efforts by patients, their fami-
lies and advocates in doing research, also called patient 
or parentled research (PLR). 
Patient or parent-led research (PLR)
Patients, their families and advocates have in the 
past often come forward to fill the research gap. Advo-
cacy groups typically drew attention to their particu-
lar needs and associated research questions; medical 
professionals and scientists subsequently developed, 
initiated, and coordinated particular research projects 
and registries, while patients and their families were in-
volved throughout different phases within this process 
[5].
Recently, however, the scientific landscape of rare 
diseases has begun to change: The increasing ac-
cess to online sources such as social networks and 
knowledge databases has given rise to the formation 
of online communities that share common interests [6 
- 8]. Today, patients network connect online easily and 
more globally than ever before [9]. They use new me-
dia not only to access health information and exchange 
experiences, but also to initiate and conduct health 
research. Approaches by these new communities in-
clude self-experimentation, self-surveillance, analyses 
of genetic information, and genome-wide associated 
studies (GWAS) [10, 11]. As a consequence, there is an 
increasing number of “crowd sourced”, “citizen-driven”, 
“participant-centric”, or “participant-led” projects sup-
ported by non-profit as well as commercial organi-
zations like CureTogether, DailyStrength, MedHelp, 
HealthChapter, MDJunction, Experience Project, Peo-
plejam, and OrganizedWisdom [12, 8, 13]. Health re-
search, initiatives appeal to large numbers of people to 
collect funding, which is then dedicated to a particular 
research project. There is a proliferation of web-based 
platforms, which aim to facilitate such initiatives [8, 
13, 14]. Almost 10’000 persons with epilepsy currently 
share their data including clinical and therapeutic de-
tails on patientslikeme.com (https://www.patients-
likeme.com/conditions/3-epilepsy). 
The parent funded Citizens United for Research in 
Epilepsy (CURE) has recently launched a patient led 
project called Epilepsy Genetic Initiative with the aim 
of uncovering the causes of epilepsy, develop precision 
treatments and design possible cures (http://www.cu-
reepilepsy.org/research/). Such patient- and parent-led 
research (PLR) has been enabled through crowd-fund-
ing. 
All these new, so-called bottom-up initiatives are 
testing the ethical and regulatory limits within which 
clinical research has traditionally operated [15]. These 
efforts have yielded some interesting results and at the 
same time they have raised some ethical questions. 
Current examples of PLR beyond clinical research
Research conducted within PLR includes self-surveil-
lance, self-experimentation, analyses of genomic data, 
and genome-wide association studies (GWAS) [16]. To 
give an idea of the powerful spectrum of PLR we de-
scribe two examples. Although there are currently only 
few PLR studies concerning epilepsy, we believe that 
PLR has the potential to support and create similar ac-
tivities for rare forms of epileptic diseases and it will be 
only a matter of time before patients with epilepsy or 
their parents will ask for these emerging possibilities.
Example 1: Amyothrophic Lateral Sclerosis (ALS)
Back in 2007 a little-noticed Italian news report was 
about a small trial, suggesting that lithium may have a 
beneficial effect for patients with ALS. A patient trans-
lated the story with the help of Google and informed 
other patients with the help of social networks in-
cluding the online platform PatientsLikeMe. Within 6 
months after publishing a small study of 16 patients 
treated with lithium 160 patients reported obtaining 
lithium off-label and tracked their health-related data 
on Google Spreadsheet including a validated functional 
rating scale. PatientsLikeMe further added tracking of 
lithium blood concentrations, data entry reminders, 
and installed support by nurses to respond to side ef-
fects. Results (with negative findings) of this rand-
omized controlled trial were openly available within 
nine months followed by a longer-term follow-up 
report (with the entire anonymised dataset as sup-
plementary material) [17]. A formal publication in the 
journal Nature Biotechnology appeared as well. 
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Example 2: Niemann-Pick Type C
Researchers and families of young patients with 
the rare disease Niemann-Pick Type C (NPC) currently 
face a remarkable problem, which is the fruit of years 
of adamant patient activism: Three companies are just 
launching three different clinical trials with new prom-
ising therapies at the same time. The current problem 
is, that the pool of eligible patients is too small to gain 
significant data for all trials, which again leads to un-
controlled competition between companies, investors 
and communities. While families fear to “lose out on 
having an approved treatment”, they have the prefer-
ence to participate right away in the most promising 
trial or to choose compassionate use of an unstudied 
therapy in fear that they won’t be among the rand-
omized or eligible participants to receive the drug. As 
a result there remain even less patients eligible for one 
of those trials [18]. In this context the journalist Amy 
Marcus reported an impressive and compassionate sto-
ry about 9-year-old twin girls affected by NPC including 
their parents’ odyssey and efforts as “citizen-scientists” 
by starting to use, to promote and to test a formerly 
unapproved therapy (cyclodextrin). While the federal 
drug administration raised concerns about potential 
side-effects, the parents started to administer cyclo-
dextrin, analyse and record urine and blood levels of 
their daughters by themselves and shared their experi-
ences with others. Their efforts finally culminated in a 
NIH-trial and a subsequent involvement of a pharma-
ceutical company, which before – due to financial con-
siderations – did not show any interests in such a trial 
before the parent/patient-led research [19].
Promised benefits of PLR
Several benefits can be derived from PLR with per-
haps the most profound being that individuals are 
enabled to become more actively involved in their own 
health. The positive effects can be seen from a value-
oriented and result-oriented point-of-view (Table 1). 
From the perspective of values PLR promises to real-
ise the basic human right of participation in scientific 
research [20]. Moreover it fosters an equal and sub-
stantial partnership between all stakeholders, such as 
patients, health care professionals, researchers and in-
dustries, which may be less constrained by geographi-
cal, financial or cultural barriers than conventional 
research. Commercial organizations such as Patient-
LikeMe or 23andMe have the potential to incorporate 
different roles and aims from all kind of stakeholders 
by supporting patients in collaboration with advocates, 
scientists, private donors/investors, industries, govern-
ments etc. From an outcome-oriented perspective PLR 
can help support, generate, personalize as well gen-
eralise health knowledge. It can open an innovative 
marketplace, which fosters new connections (including 
funding) between previously unrelated sources and, 
if trials are made transparent, participants and others 
will be informed faster about positive or negative ef-
fects of a certain treatment or intervention independ-
ent of other stakeholder’s interests [21]. Especially 
negative findings like new side effects can be discussed 
openly and benefits can be judged and weighed by pa-
tients or parents in terms of their individual needs and 
values. Moreover mechanisms like social networks, 
crowd-funding, and public recruitment of participants 
can facilitate diagnosis, trial enrolment and treatment 
for a a larger patients group. It also may thereby help 
Table 1:  Advantages of using and promoting PLR
Promised Benefits
Value-oriented perspective
• Participation by having a greater voice in medicine 
• Substantial and equal partnership between all stakeholders
• Foster adequate reflection of perspectives and input of citizens.
• More accurate priorization of outcomes patients and families truly value
• Translating trial results to the “real world” of patients and families
 
Outcome-oriented perspective
• Enabling research in unfunded or underfunded areas
• Producing generalisable health knowledge
• Benefit for a bigger number of patients
• Benefit for the wider society
• Easy and better recruiting/enrolment of participants
• Deliver results about positive and negative effects more rapidly
• Greater self knowledge
180 Epileptologie 2015; 32 The Promising Revolution of Participant-Led Research... | J. C. Streuli, E. Vayena
society at large by supporting patients and families to 
achieve greater (self) knowledge and increased respon-
sibility for their own health and their health promoting 
behaviour.
Emerging ethical questions and problems with 
PLR
While the potential of patients’ communities and 
their involvement in the rare disease research agenda 
can play a catalytic role in the development of diagnos-
tics and treatments, they certainly do pose a new set of 
ethical questions: How can PLR comply with rigid scien-
tific standards, which are needed to add relevant and 
useful data to the standard scientific community? And 
how can PLR be conducted ethically? Table 2 gives an 
overview of identified ethical problems related to PLR. 
Basically the ethical questions arise from (potentially) 
harmful decisions or actions (1), failure to render (op-
timal or necessary) assistance (2), injustice (3) or disre-
spect of autonomy (4). Different questions and prob-
lems do concern stakeholders in different ways. While 
parents may struggle with multitude of promising but 
uncertain therapy options, researchers, health care 
professionals, sponsors and the state have to reason 
about their responsibility and duty regarding patients 
and their parents. How should clinical research institu-
tions respond to parental requests about organizing a 
research project involving their children, i.e. suggest-
ing an off-label use of a drug? How should institutions 
respond to parental requests for data-sharing with 
other researchers or bottom-up online research pro-
jects? How should medical professionals, searching for 
new therapeutic and diagnostic methods, respond to 
the methodological challenges of these new research 
forms, including self-selection and self-reporting of 
symptoms or phenotypic data [16, 22]. In particular, 
what additional risks may such initiatives carry for chil-
dren when they are involved in projects that have not 
gone through the standard research review systems? 
For example, PLR bypasses control mechanisms, which 
ensure enough preclinical evidence before launching 
clinical trials. 
PLR changes not only the structure of research but 
also the relationships between all stakeholders in-
volved. It may undermine current mechanism for pro-
tecting patients, researchers and funding bodies in-
cluding the traditions research system, that are aiming 
to ensure reliable medical evidence (and subsequent 
confidence) [23]. So finally the questions culminate in 
how the energy and the potential of those initiatives 
can be harnessed and steered to fill the large gaps in 
clinical rare disease research. 
There are currently neither consensus nor common 
guidelines, which help stakeholders to deal with these 
questions.  
A way forward 
Keeping the presented benefits and pitfalls in mind 
clinicians and standard research institutions have to 
develop responsive mechanisms to these new initia-
tives. Such mechanisms should aim to foster partner-
ships between these communities and the standard 
Table 2: Emerging ethical questions and problems with PLR
• Lack of/uncertainty about adequate information and consent/assent in terms of potential harm and alternatives
• Limits of parental authority in enrolment of their child in PLR
• Endangerment of traditional social values such as dignity, privacy and justice
• Inadequate and/or unnecessary risks by self-experimentation
• Peer pressure to participate in trial
• Exploitation of vulnerable individuals in desperate search of help
• Bias and distortion arising from the use of self-reported and self-collected symptoms and data
• Bias by heterogeneity of participants
• Lack of overview and difficult regulation of PLR by heterogeneity of participants
• Blurring boundaries between treatment, self-experimentation and life-style driven enhancement
• Missing acceptance of PLR as an authentic mode of research: obstacles in conducting research and publishing     
 results
• No regulations concerning quality control and security by undermining current state-of-art concerning 
 professionalism and ethics
• Uncertainty how to use results of PLR in terms of validity and evidence in clinical therapy
• Study enrolment with risks of harm in the light of inadequate methodology
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scientific establishment while ensuring that ethical 
standards are respected. Scholars have only begun to 
study these new challenges and recent work has of-
fered recommendations for how participant-led re-
search can be ethically conducted [20, 24]. Table 3 gives 
an overview of some accompanying measures to imple-
ment PLR. In general PLR seems to have arisen largely in 
reaction to the seclusion of science in the ‘ivory tower’ 
of science and regulation that despite its spirit has sti-
fled innovative research [25]. In combination with the 
lack of a broader research agenda for a specific rare dis-
ease and the lack of any treatment, there is a strong in-
terest of parents to seek out research projects, to fund 
some, some, or to generate research projects involving 
their sick children. Therefore, a “top down” regulation 
deriving from established institutions seems unlikely 
to be successful. The most promising way seems to use 
the language and culture, which PLR is just establish-
ing by : directly engaging with the affected commu-
nity [17, 25]. Existing legal and ethical frameworks can 
help to address some of the ethical challenges in PLR: 
e.g.Interference with parental authority is justified and 
required if children were exposed to significant harm 
[20]. But neither existing ways of communication, nor 
currently operating ethical and legal review boards 
seem to be sufficient for this new task. The question of 
how to define “significant” harm has to be answered 
on individual basis as most situations in PLR are unique 
and have no precedent. Second, PLR activities do not 
have yet a clear control mechanism and may have no 
incentives to restrict their newly gained possibilities by 
such a mechanism. Third, existing control mechanisms 
(such as ethics review committees, IRBs) may have 
limited capacities and mandates for providing over-
sight to PLR activities. 
While PLR activities need societal acceptance of 
their role and of their  added value despite being out-
side of the scientific mainstream, they also need clearly 
defined standard for high scientific research quality 
[23]. Mutual responsibilities that address the needs of 
different stakeholders should be discussed and defined 
within the public domain[ 20]. For example, to provide 
scientific advice on research proposals, existing agen-
cies could foster publicly funded panels of experts [23].
Finally established researches and research institu-
tions should help to develop journal appraisal systems 
that are receptive to submissions of results from PLR. 
As a result such journals in addition to existing online 
communities can help to foster an on-going dialogue 
about benefits, pitfalls and further responsive mecha-
nisms (more detailed steps listed in Table 2). 
It is likely to expect that patients and their fami-
lies dealing with disease will have increased scientific 
understanding and subsequently will feel confident to 
take more responsibility for research and implementa-
tion of research outcomes in practice [26]. In our opin-
ion there is neither a way nor a reason to suppress this 
on-going revolution but it is now the time to think criti-
cally and creatively about how this can contribute to 
better scientific research and ultimately to a better and 
more just health care. 
Table 3: Accompanying measures and responsive mechanisms
• To („creatively“) apply existing legal frameworks
• To gain a deeper understanding of available possibilities and current practices of PLR
• To comprehend that different activities within PLR may require different procedures
• To accept research issues outside of the scientific mainstream
• To promote shared decision-making amongst stakeholders
• To recognize PLR as a valuable means of contributing to generalizable health knowledge
• To provide material support for PLR, incorporating its outputs in standard research
• To support reciprocal responsibilities of all stakeholders
• To establish uniform ethical and scientific standards
• To distribute publicly accessible set of standards for its oversight
• To support „transparent“ and „open“ manner of communicating about study design, results and their meaning
• To develop an online platform where PLR activities may be publicly registered
• To provide scientific advice on research proposals through publicly funded panels of experts
• To create online tools, including scientific and ethical checklists of relevant considerations
• To develop journal appraisal systems that are known to be receptive to submissions of results from PLR.
• To foster ongoing dialogue about benefits, pitfalls and responsive mechanisms
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